Tasigna and Ejection fraction decreased - a phase IV clinical study of FDA data

Summary:

Ejection fraction decreased is reported as a side effect among people who take Tasigna (nilotinib hydrochloride monohydrate), especially for people who are 60+ old, have been taking the drug for < 1 month also take Flovent, and have High blood cholesterol.

The phase IV clinical study analyzes which people have Ejection fraction decreased when taking Tasigna. It is created by eHealthMe based on reports of 31,413 people who have side effects when taking Tasigna from the FDA, and is updated regularly.

What is Tasigna?

Tasigna has active ingredients of nilotinib hydrochloride monohydrate. It is often used in chronic myelogenous leukemia (cml). eHealthMe is studying from 31,535 Tasigna users. Check the latest studies of Tasigna.

What is Ejection fraction decreased?

Ejection fraction decreased (systolic heart failure) is found to be associated with 1,066 drugs and 1,252 conditions by eHealthMe. Check the latest studies of Ejection fraction decreased.

On Jul, 06, 2026

31,413 people reported to have side effects when taking Tasigna.
Among them, 75 people (0.24%) have Ejection fraction decreased.

$Could Tasigna cause Ejection fraction decreased?$

Among these 75 people:

How long have people been on Tasigna when they have Ejection fraction decreased? *

What is the age of people who have Ejection fraction decreased when taking Tasigna? *

What are other drugs people take besides Tasigna? *

What are other side effects people have besides Ejection fraction decreased? *

Fatigue (feeling of tiredness): 24 people, 32.00%
Dyspnea (difficult or laboured breathing): 20 people, 26.67%
Abdominal Pain Upper: 17 people, 22.67%
Cardiac Failure: 16 people, 21.33%
Rashes (redness): 15 people, 20.00%
Malaise (a feeling of general discomfort or uneasiness): 15 people, 20.00%
Chest Pain: 14 people, 18.67%
Electrocardiogram Abnormal: 14 people, 18.67%
Indigestion: 13 people, 17.33%
Eye Haemorrhage (bleeding in the eye): 12 people, 16.00%

What are the existing conditions these people have? *

High Blood Cholesterol: 12 people, 16.00%
High Blood Pressure: 10 people, 13.33%
Depression: 5 people, 6.67%
Acute Myeloid Leukaemia (acute cancer in which the bone marrow makes abnormal myeloblasts): 4 people, 5.33%
Arterial Occlusive Disease (slow process through which arteries throughout the body become progressively narrowed and eventually completely blocked): 4 people, 5.33%
Oedema (fluid collection in tissue): 4 people, 5.33%
Cardiac Failure: 3 people, 4.00%
Acute Lymphocytic Leukemia (All) (cancer of the white blood cells characterized by excess lymphoblasts): 2 people, 2.67%
Asthma: 2 people, 2.67%
Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 2 people, 2.67%

* Approximation only. Some reports may have incomplete information.

Do you take Tasigna and have Ejection fraction decreased?

- Check whether Ejection fraction decreased is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Tasigna:

Tasigna (31,535 reports)

Ejection fraction decreased treatments and more:

Ejection fraction decreased (19,545 reports)

How severe was Ejection fraction decreased and when was it recovered:

Ejection fraction decreased in Tasigna

Expand to all the drugs that have ingredients of nilotinib hydrochloride monohydrate:

Ejection fraction decreased and drugs with ingredients of nilotinib hydrochloride monohydrate (80 reports)

Sub-studies by age:

0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Tasigna:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Ejection fraction decreased:

Ejection fraction decreased (1,066 drugs)

Browse all the conditions that are associated with Ejection fraction decreased:

Ejection fraction decreased (1,252 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on nilotinib hydrochloride monohydrate (the active ingredients of Tasigna) and Tasigna (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.